TICKERNERD
Menu
ZTSZTSHealthcare · Drug Manufacturers - Specialty & Generic

ZTS Stock Forecast: Zoetis, Inc. Price Predictions for 2026-2027

Last close, 6 Oct 2026
$71
−0.11% on the day

The 17 Wall Street analysts covering Zoetis, Inc. hold a median 12-month price target of $90 — +25.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 43 of 100 as at 6 Oct 2026 — in the lower half.

Market cap
$29.5B
Ticker Nerd rank
43 / 100
Median analyst target
$90
Analysts covering
17
Revenue$2.5B+0.3% y/y
Operating income$999.0M
Net income$691.0M
Free cash flow$538.0M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+1.5%
1M
−5.9%
YTD
−42.4%
1Y
−50.0%
From 52W high
−50.7%
From 52W low
+3.2%
$69
$145
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

ZTS stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Zoetis, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 6 Oct 2026
43 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Volatility
99
Value
98
Quality
96
Issuance
51
Growth
48
Accruals
38
Revisions
32
Size
8
Momentum
7

Volatility (99): The share price has been relatively steady.

Momentum (7): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

ZTS stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ZTS, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$60$80$100$120$140$160Jan 26Apr 26Jul 26Oct 26ZTSHigh $155Median $90Low $80

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says17 analysts
8 Buy9 Hold0 Sell
Low $80Median $90High $155

The green dot is the last close — the median target sits +25.5% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 0 moved their price target up and 10 moved it down.

DateFirmActionRatingTarget
25 Aug 2026TD CowenMaintainsBuy$104 → $94
20 Aug 2026StifelMaintainsHold$85 → $80
11 Aug 2026BNP ParibasMaintainsOutperform—
11 Aug 2026BNP ParibasMaintainsOutperform$146 → $110
11 Aug 2026CitigroupMaintainsBuy—
11 Aug 2026CitigroupMaintainsBuy$112 → $96
10 Aug 2026Piper SandlerMaintainsNeutral$90 → $80
10 Aug 2026Piper SandlerMaintainsNeutral—
7 Aug 2026JP MorganMaintainsOverweight—
7 Aug 2026JP MorganMaintainsOverweight$130 → $115
7 Aug 2026UBSMaintainsNeutral—
7 Aug 2026UBSMaintainsNeutral$85 → $80
6 Aug 2026William BlairDowngradeMarket Perform—
6 Aug 2026William BlairDowngradeMarket Perform—
27 July 2026UBSMaintainsNeutral$99 → $85
27 July 2026UBSMaintainsNeutral—
22 July 2026Morgan StanleyMaintainsOverweight$115 → $99
22 July 2026Morgan StanleyMaintainsOverweight—
6 July 2026HSBCMaintainsBuy—
6 July 2026HSBCMaintainsBuy$140 → $95

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ZTS appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

ZTS vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 6 Oct 2026, Zoetis, Inc. returned −50.0% against +17.3% for the S&P 500, dividends included.

ZTS vs S&P 500, last 12 monthsTotal return, rebased to 100
406080100120Jan 26Apr 26Jul 26Oct 26ZTSS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

ZTS analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
−9.8%
Analysts raising
0
Analysts cutting
15
Fundamentals

Zoetis, Inc. (ZTS) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
11.7×

Cheaper than 54% of US stocks

Price / sales
3.1×

Cheaper than 39% of US stocks

Price / book
9.1×

Cheaper than 10% of US stocks

EV / EBITDA
9.1×

Cheaper than 40% of US stocks

Growth & margins
Revenue growth (YoY)
−0.2%

Higher than 27% of US stocks

Earnings growth (YoY)
−4.8%

Higher than 31% of US stocks

Gross margin
72.7%

Higher than 85% of US stocks

Operating margin
40.7%

Higher than 92% of US stocks

Net margin
27.7%

Higher than 87% of US stocks

Returns & dividend
Return on equity
64.9%

Higher than 94% of US stocks

Return on assets
15.4%

Higher than 97% of US stocks

Dividend yield
3.0%

Higher than 85% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Zoetis, Inc. (ZTS) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Zoetis, Inc. has a market value of $29.5B and an enterprise value of $37.1B.

  • Revenue in the twelve months to 30 June 2026: $9.5B. The latest quarter shrank 0.2% year on year.

  • Net income over the same four quarters: $2.6B, a 27.5% net margin.

  • Diluted earnings per share, trailing twelve months: $6.07.

  • Free cash flow in the twelve months to 30 June 2026: $2.3B, after $524.0M of capital spending.

  • Zoetis, Inc. spent $3.6B on share buybacks and $889.0M on dividends in the twelve months to 30 June 2026.

  • Shares outstanding: 414.2M.

  • Trailing P/E: 11.7×; forward P/E: 10.9× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 2.97%, paying out 34% of earnings.

  • Zoetis, Inc. employs 14,500 people — $656K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 7 Oct 2026

Data provided by Twelve Data

Peers

ZTS vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDrug Manufacturers - Specialty & Generic
CompanyMarket capTKN rank
ZTSZoetis, Inc.$29.5B
43
UTHRUnited Therapeutics Corp.$23.0B
81
VTRSViatris, Inc.$20.2B
100
NBIXNeurocrine Biosciences, Inc.$14.5B
87
ELANElanco Animal Health, Inc.$11.2B
97
ALKSAlkermes Plc$6.9B
61
HIMSHims & Hers Health, Inc.$6.9B
17

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Zoetis, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest ZTS news & analysis

New Peer-Reviewed Publication on Laboratory Study That Demonstrated Simparica Trio® Protected 3x More Dogs From Infection With a Resistant Heartworm Isolate Than NexGard® Plus1

Business Wire · 6 Oct 2026positive

A new peer-reviewed publication reports that, in a laboratory study, Simparica Trio protected three times more dogs from infection with a resistant heartworm isolate than NexGard Plus. The excerpt describes macrocyclic lactone resistance as a growing challenge for heartworm prevention.

Why it matters — The study concerns a Zoetis product and evidence on its performance against a resistant heartworm isolate, an issue highlighted as relevant to veterinarians and pet owners.

Zoetis (ZTS) Stock Sinks As Market Gains: Here's Why

Zacks Investment Research · 1 Oct 2026negative

Zoetis (ZTS) shares closed at $69.1 in the latest trading day, down 1.05% from the prior close, a decline that came even as the broader market gained.

Why it matters — The stock's decline against a rising market may be relevant to investors tracking Zoetis's recent trading performance.

Top 25 Attractive Dividend Stocks For October 2026

Seeking Alpha · 1 Oct 2026neutral

Seeking Alpha published a screened Top 25 U.S. dividend growth stock list for October 2026, highlighting stocks with yields above 2.5%, an average 3.38% dividend yield, and undervaluation of roughly 31% by dividend yield theory. The list includes subsets focused on high-yield, fast dividend growth, highest expected return, and most undervalued opportunities.

Why it matters — ZTS watchers may find this list useful as a reference point for comparing Zoetis's dividend characteristics against other top dividend growth stocks, even though the excerpt does not specify whether ZTS is included.

Zoetis: Priced For The Worst, Worth Buying

Seeking Alpha · 30 Sept 2026positive

Zoetis has fallen 71% from its 2021 peak and now trades at 2017 levels, with eroded pricing power and declining pet medicine volumes. Despite these near-term headwinds, the company retains industry-leading margins and is positioned to fare better than rivals in price wars due to its product mix and scale, with a pipeline of 12 candidates that could offset expected patent expiries for Apoquel and Simparica.

Why it matters — The article highlights that Zoetis retains competitive advantages and a pipeline that could offset key patent-expiry risks, suggesting the current low valuation may not reflect the company's longer-term resilience.

Zoetis (ZTS) Registers a Bigger Fall Than the Market: Important Facts to Note

Zacks Investment Research · 24 Sept 2026negative

Zoetis (ZTS) closed at $70.27 in the most recent trading session, a -1.87% decline from the previous trading day, falling more than the broader market.

Why it matters — The stock underperformed the market in the session, which ZTS watchers would note as a sign of recent trading weakness.

FAQ

Frequently asked questions about ZTS stock

What is the ZTS stock price forecast for 2026-2027?

The 17 Wall Street analysts covering Zoetis, Inc. have a median 12-month price target of $90, with estimates ranging from $80 to $155. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ZTS stock a buy right now?

Of the 17 analysts covering Zoetis, Inc., 8 rate it a Buy, 9 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Zoetis, Inc. 43 out of 100 across roughly 4,600 US stocks as at 6 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ZTS?

As at 6 Oct 2026, Zoetis, Inc. ranks 43 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (99 of 100).

Will ZTS stock go up?

No one can know that. What the data says: the median 12-month target from 17 analysts implies +25.5% from the last close, and Ticker Nerd's factor model ranks Zoetis, Inc. 43 out of 100 as at 6 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ZTS stock forecast for 2030?

No analyst covering Zoetis, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ZTS are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $80 to $155 over the next 12 months.

How has ZTS stock performed over the past year?

Zoetis, Inc. returned -50.0% over the 12 months to 6 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Zoetis, Inc. do?

Zoetis Inc. Class A Common Stock represents Zoetis, a global animal health company focused on medicines, vaccines, diagnostics, and related technologies for pets and livestock.

What is the latest news on ZTS?

The most recent item we track (Business Wire, 6 Oct 2026): "New Peer-Reviewed Publication on Laboratory Study That Demonstrated Simparica Trio® Protected 3x More Dogs From Infection With a Resistant Heartworm Isolate Than NexGard® Plus1". A new peer-reviewed publication reports that, in a laboratory study, Simparica Trio protected three times more dogs from infection with a resistant heartworm isolate than NexGard Plus. The excerpt describes macrocyclic lactone resistance as a growing challenge for heartworm prevention.

Company

About Zoetis, Inc.

Zoetis Inc. Class A Common Stock represents Zoetis, a global animal health company focused on medicines, vaccines, diagnostics, and related technologies for pets and livestock. Zoetis develops and markets products used by veterinarians, livestock producers, and pet owners across companion animals such as dogs, cats, and horses, as well as livestock including cattle, swine, poultry, fish, and sheep. Its portfolio includes parasiticides, dermatology treatments, pain and sedation products, anti-infectives, diagnostic tools, genetic tests, and precision animal health solutions. The company also provides reference laboratory services, rapid tests, instruments, and other non-pharmaceutical offerings that support disease detection and animal care. Headquartered in Parsippany, New Jersey, Zoetis operates in the United States and international markets, serving a broad range of animal health needs across clinical, agricultural, and diagnostic settings.

CEO Ms. Kristin C. Peck · 14,500 employees · United States · https://www.zoetis.com